Acquisition of OXB France

On January 29th, 2024, Oxford Biomedica plc acquired OXB France. The acquisition of OXB France, a pure-play European CDMO, strengthens Oxford Biomedica’s position as a world-leading cell and gene therapy CDMO. This strategic move broadens the Company’s international development, manufacturing and testing presence, services, and capacity by establishing a strong footprint within the EU with facilities in Lyon and Strasbourg, France. In addition, the acquisition increases Oxford Biomedica’s capacity in process and analytical development and early- stage manufacturing across Adenovirus, Lentiviral vectors, AAVs, and with this acquisition, MVA and Vaccinia. For more information on the acquisition, see the press release links below.

Press Releases

Oxford Biomedica completes acquisition of ABL (Europe)

Oxford, UK – 29 January 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that, following the announcements on 20 September and 4 December 2023, it has today completed the acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA (“Institut Mérieux”).

Oxford Biomedica signs agreement to acquire ABL (Europe) from Institut Mérieux, consolidating position as a global pure-play CDMO

Oxford, UK – 4 December 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that it has entered into a sale and purchase agreement (the “Agreement”) with TSGH SAS, a subsidiary of Institut Mérieux SA (“Institut Mérieux”), for the acquisition of ABL Europe SAS (“ABL Europe”) (the “Transaction”). This follows the announcement on 20 September 2023, of exclusive negotiations in relation to the proposed acquisition by Oxford Biomedica of ABL Europe, a pure-play European CDMO with specialised expertise in the development and manufacturing of solutions for biotechs and biopharma including viruses for gene therapy, oncolytic viruses and vaccine candidates, in exchange for Oxford Biomedica ordinary shares.

Announcement of proposed acquisition by Oxford Biomedica of ABL (Europe)

Oxford, UK – 20 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, and Institut Mérieux SA (“Institut Mérieux”) today announce that they have entered into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe SAS (“ABL Europe”), a pure play European CDMO with specialised expertise in the development and manufacturing of solutions for biotechs and biopharma including viruses for gene therapy, oncolytic viruses and vaccine candidates, in exchange for Oxford Biomedica ordinary shares (the “Proposed Transaction”).